8-K: Genprex Faces Nasdaq Delisting Risk

Genprex, Inc. received a Nasdaq delisting notice for failing to maintain a minimum $1.00 bid price and intends to request a hearing.

Summary

• Genprex received a deficiency notice from Nasdaq on June 10, 2026, for failing to maintain a minimum bid price of $1.00 per share.
• The company is ineligible for a standard 180-day compliance period due to a reverse stock split effected on October 21, 2025.
• Management intends to request a hearing before a Nasdaq Hearings Panel to stay any immediate delisting action.
• The company is considering a potential reverse stock split as a mechanism to regain compliance with listing requirements.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development, as the loss of Nasdaq compliance and the potential need for another reverse stock split indicate significant market pressure and financial instability.

Positives

• The company is proactively engaging with the Nasdaq Hearings Panel to stay delisting proceedings.
• Management has clearly identified potential remedial actions, including a possible reverse stock split, to address the deficiency.

Negatives

• The company is currently in violation of Nasdaq Listing Rule 5550(a)(2).
• Ineligibility for the standard 180-day compliance period increases the urgency and risk of the situation.
• The potential for a second reverse stock split within a short timeframe may signal ongoing financial or market valuation challenges.

Risks

• Potential delisting from The Nasdaq Capital Market could lead to reduced liquidity and lower share prices.
• Delisting may impair the company's ability to raise capital through traditional financing sources.
• A reverse stock split may not result in a proportionate increase in share price or sustained compliance.
• Loss of investor confidence and potential negative impact on business development opportunities.

Future Outlook

The company intends to request a hearing before the Nasdaq Panel to stay delisting and will explore options, including a potential reverse stock split, to regain compliance with the $1.00 minimum bid price requirement.

Management Comments

• The company intends to timely request a hearing before the Panel.
• The company intends to continue to take definitive steps in an effort to evidence compliance with the Bid Price Requirement.

Industry Context

StockSavvy.ai notes that small-cap biotechnology firms frequently face Nasdaq compliance challenges due to high volatility and capital-intensive R&D cycles, often necessitating reverse splits to maintain listing status.

Comparison to Industry Standards

• The reliance on reverse stock splits to maintain Nasdaq compliance is a common, albeit often viewed negatively, strategy among micro-cap biotech companies.
• The inability to utilize the 180-day grace period due to a recent prior split places the company in a more precarious position than peers who have not recently restructured their share count.

Stakeholder Impact

• Shareholders face potential volatility and risk of delisting.
• Employees and business partners may experience uncertainty regarding the company's long-term stability.
• Creditors and potential investors may view the company as a higher risk profile.

Next Steps

• Submit a formal request for a hearing before the Nasdaq Hearings Panel.
• Monitor the closing bid price of common stock.
• Evaluate the implementation of a reverse stock split to regain compliance.

Key Dates

Recommendation

The combination of a Nasdaq delisting notice and the exhaustion of standard compliance grace periods suggests significant underlying financial distress, making the stock highly speculative and risky for institutional investors.

Keywords

Genprex, GNPX, Nasdaq, delisting, reverse stock split, compliance, biotech, minimum bid price